• Report from the ESMO 2018 presidential symposium-Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE. 

  Parker, C (2018)
• Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. 

  Abu Zaid, M; Dinh, PC; Monahan, PO; Fung, C; El-Charif, O; Feldman, DR; Hamilton, RJ; Vaughn, DJ; Beard, CJ; Cook, R; Althouse, S; Ardeshir-Rouhani-Fard, S; Sesso, HD; Huddart, R; Mushiroda, T; Kubo, M; Dolan, ME; Einhorn, LH; Fossa, SD; Travis, LB; Platinum Study Group (2019-05-01)

  BACKGROUND: This study examined the prevalence of hypogonadism, its clinical and genetic risk factors, and its relationship to adverse health outcomes (AHOs) in North American testicular cancer survivors (TCS) after modern ...
• Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment. 

  Evgin, L; Huff, AL; Kottke, T; Thompson, J; Molan, AM; Driscoll, CB; Schuelke, M; Shim, KG; Wongthida, P; Ilett, EJ; Smith, KK; Harris, RS; Coffey, M; Pulido, JS; Pandha, H; Selby, PJ; Harrington, KJ; Melcher, A; Vile, RG

  Antitumor T-cell responses raised by first-line therapies such as chemotherapy, radiation, tumor cell vaccines, and viroimmunotherapy tend to be weak, both quantitatively (low frequency) and qualitatively (low affinity). ...
• Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. 

  Brown, LC; Ahmed, HU; Faria, R; El-Shater Bosaily, A; Gabe, R; Kaplan, RS; Parmar, M; Collaco-Moraes, Y; Ward, K; Hindley, RG; Freeman, A; Kirkham, A; Oldroyd, R; Parker, C; Bott, S; Burns-Cox, N; Dudderidge, T; Ghei, M; Henderson, A; Persad, R; Rosario, DJ; Shergill, I; Winkler, M; Soares, M; Spackman, E; Sculpher, M; Emberton, M

  BACKGROUND: Men with suspected prostate cancer usually undergo transrectal ultrasound (TRUS)-guided prostate biopsy. TRUS-guided biopsy can cause side effects and has relatively poor diagnostic accuracy. Multiparametric ...
• From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. 

  Hussain, SA; Birtle, A; Crabb, S; Huddart, R; Small, D; Summerhayes, M; Jones, R; Protheroe, A

  CONTEXT: A number of PD-1/PD-L1 inhibitors have recently been approved for use in patients with locally advanced or metastatic urothelial carcinoma (UC) on the basis of results from several clinical trials. OBJECTIVE: To ...

View more